Close Menu

NEW YORK – Invitae announced Wednesday evening that it has priced a $160 million public offering of 17,777,778 shares of common stock.

The offering was priced at $9.00 per share and is slated to close on April 6. Invitae is also granting underwriters a 30-day option to purchase an additional 2,666,666 shares of common stock at the same price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.